← Back to Clinical Trials
Recruiting NCT05205343

NCT05205343 Trans-Pacific Multicenter Collaborative Study of Minimally Invasive Proximal Versus Total Gastrectomy for Proximal Gastric and Gastroesophageal Junction Cancers

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05205343
Status Recruiting
Phase
Sponsor M.D. Anderson Cancer Center
Condition Gastrostomy
Study Type OBSERVATIONAL
Enrollment 20 participants
Start Date 2022-05-11
Primary Completion 2026-05-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Standard of CareControl Group

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 20 participants in total. It began in 2022-05-11 with a primary completion date of 2026-05-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

To compare the symptoms of patients who have a MIPG to the symptoms of patients who have a MITG.

Eligibility Criteria

Inclusion: 1. Able to speak and read English, Spanish, Japanese or Korean 2. Participants with a biopsy-confirmed diagnosis of non-metastatic gastric or GEJ adenocarcinoma, who are scheduled to undergo MIPG or MITG for curative-intention 3. Age ≥ 18 Exclusion: 1. Participants with known malabsorption syndromes or a lack of physical integrity of the upper gastrointestinal tract 2. Participants with known narcotic dependence, with average daily dose \> 5 mg oral morphine equivalent 3. Participants deemed unable to comply with study and/or follow-up procedures, at investigators' discretion 4. Participants who are pregnant (since are excluded from receiving standard-of-care MIPG or MITG)

Contact & Investigator

Central Contact

Naruhiko Ikoma, MD

✉ nikoma@mdanderson.org

📞 (832) 729-2675

Principal Investigator

Naruhiko Ikoma, MD

PRINCIPAL INVESTIGATOR

M.D. Anderson Cancer Center

Frequently Asked Questions

Who can join the NCT05205343 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Gastrostomy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05205343 currently recruiting?

Yes, NCT05205343 is actively recruiting participants. Contact the research team at nikoma@mdanderson.org for enrollment information.

Where is the NCT05205343 trial being conducted?

This trial is being conducted at Rochester, United States, Houston, United States, Tokyo, Japan, Soeul, South Korea.

Who is sponsoring the NCT05205343 clinical trial?

NCT05205343 is sponsored by M.D. Anderson Cancer Center. The principal investigator is Naruhiko Ikoma, MD at M.D. Anderson Cancer Center. The trial plans to enroll 20 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology